COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ethyl-EPA Treatment of Prodromal Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00634361
Recruitment Status : Completed
First Posted : March 13, 2008
Last Update Posted : May 22, 2014
Information provided by (Responsible Party):
Yale University

Brief Summary:
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Condition or disease Intervention/treatment Phase
Schizophrenia Prodrome Drug: ethyl-eicosapentaenoic acid Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ethyl-EPA Treatment of Prodromal Patients
Study Start Date : September 2001
Actual Primary Completion Date : August 2005
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: A Drug: ethyl-eicosapentaenoic acid
2 mg per day
Other Name: ethyl-EPA, an omega-3 fatty acid

Primary Outcome Measures :
  1. conversion to psychosis [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • meets criteria for schizophrenia prodrome

Exclusion Criteria:

  • any lifetime antipsychotic treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00634361

Sponsors and Collaborators
Yale University
Layout table for investigator information
Principal Investigator: Scott W Woods, MD Yale University
Layout table for additonal information
Responsible Party: Yale University Identifier: NCT00634361    
Obsolete Identifiers: NCT00237835
Other Study ID Numbers: LA01.03.0011
First Posted: March 13, 2008    Key Record Dates
Last Update Posted: May 22, 2014
Last Verified: May 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders